Rates of Decline in Alzheimer Disease Decrease with Age
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Age is the strongest risk factor for sporadic Alzheimer disease (AD), yet the effects of age on rates of clinical decline and brain atrophy in AD have been largely unexplored. Here, we examined longitudinal rates of change as a function of baseline age for measures of clinical decline and structural MRI-based regional brain atrophy, in cohorts of AD, mild cognitive impairment (MCI), and cognitively healthy (HC) individuals aged 65 to 90 years (total n = 723). The effect of age was modeled using mixed effects linear regression. There was pronounced reduction in rates of clinical decline and atrophy with age for AD and MCI individuals, whereas HCs showed increased rates of clinical decline and atrophy with age. This resulted in convergence in rates of change for HCs and patients with advancing age for several measures. Baseline cerebrospinal fluid densities of AD-relevant proteins, Aβ(1-42), tau, and phospho-tau(181p) (ptau), showed a similar pattern of convergence with advanced age across cohorts, particularly for ptau. In contrast, baseline clinical measures did not differ by age, indicating uniformity of clinical severity at baseline. These results imply that the phenotypic expression of AD is relatively mild in individuals older than approximately 85 years, and this may affect the ability to distinguish AD from normal aging in the very old. Our findings show that inclusion of older individuals in clinical trials will substantially reduce the power to detect disease-modifying therapeutic effects, leading to dramatic increases in required clinical trial sample sizes with age of study sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · cited 1×
“To evaluate baseline region of interest (ROI) measurements, we used a structural MRI postprocessing technique that automatically delineates subcortical [25] and cortical [26] ROIs.”
MethodSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“Pathologically, AD is characterized by the misfolding [7–9] and accumulation of amyloid-beta (Ab) and tau proteins in insoluble aggregates, leading to the formation of amyloid plaques and neurofibrillary tangles (NFTs) [10,11].”
BackgroundBraak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“However, the ROIs impacted by NFTs in earliest stages of the disorder (Braak stages I– II, transentorhinal, and stage III, limbic [38,39]) continued to show significant differences in rates of decline for patients and older controls at more advanced ages, although differences were smaller than those observed at younge…”
Within-subject template estimation for unbiased longitudinal image analysis
Reuter, M., Schmansky, N. J., Rosas, H. D., & Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.084 · Cited by 2,356
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Unfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506 · cited 1×
“Pathologically, AD is characterized by the misfolding [7–9] and accumulation of amyloid-beta (Ab) and tau proteins in insoluble aggregates, leading to the formation of amyloid plaques and neurofibrillary tangles (NFTs) [10,11].”
BackgroundAge, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900 · cited 11×
“However, the ROIs impacted by NFTs in earliest stages of the disorder (Braak stages I– II, transentorhinal, and stage III, limbic [38,39]) continued to show significant differences in rates of decline for patients and older controls at more advanced ages, although differences were smaller than those observed at younge…”
BackgroundResultInfluentialAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806 · cited 1×
“Age is the strongest risk factor for sporadic Alzheimer disease (AD) [1,2], the most common cause of dementia.”
BackgroundNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 1×
“The increase in burden of these hallmark AD lesions in normal aging [12–14], combined with the increasing inability of aging cells to maintain disease proteins in benign states [15] and the exponential growth in the incidence of AD with increasing age (at least through approximately 85 years [16]), could suggest that…”
BackgroundBuerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Dementia incidence continues to increase with age in the oldest old: The 90+ study
Corrada, M. M., Brookmeyer, R., Paganini‐Hill, A., Berlau, D., & Kawas, C. H. (2010) · Annals of Neurology · doi:10.1002/ana.21915 · Cited by 523 · cited 1×
“contrast, the 90+ Study examining all-cause dementia, including 60% of participants diagnosed with AD, had a larger contingent of oldest participants, and found that dementia incidence continued to increase with age [57].”
ResultConsistent neuroanatomical age-related volume differences across multiple samples
Walhovd, K. B., Westlye, L. T., Amlien, I., Espeseth, T., Reinvang, I., Raz, N., Agartz, I., Salat, D. H., Greve, D. N., Fischl, B., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.013 · Cited by 506 · cited 1×
“Our results showing smaller baseline structure size in older as compared with younger participants, modeled using linear fits with age, are in broad agreement with earlier manual and automated volumetry analyses [47–49].”
ResultSelf-citationAPOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397 · cited 1×
“For example, the Cache County Study [53–55] and an autopsy study [56] found that incidence rates of AD decrease, beginning in the early 90 s.”
MethodAlzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211 · cited 1×
“Methodological bias in image registration leading to elevated effect sizes remains a concern in the AD structural neuroimaging literature [24], particularly given recent reports [27–32] of results that are ostensibly corrected for bias but in fact, as shown in [24], remain significantly biased.”
ResultSubregional neuroanatomical change as a biomarker for Alzheimer's disease
Holland, D., Brewer, J. B., Hagler, D. J., Fennema-Notestine, C., Dale, A. M., Initiative, T. A. D. N., Weiner, M., Thal, L., Petersen, R., Jack, C. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906053106 · Cited by 210 · cited 2×
“The number of followup scans was reduced by approximately 15% primarily due to motion artifacts, change in scanner model, or change in RF coil, as described in [22].”
BackgroundMethodSelf-citationKhachaturian, A. S. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.5.518 · Cited by 176
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145 · cited 1×
“A recent investigation [68] of the shapes of AD biomarker trajectories examined whether, as suggested by sigmoidal models, hippocampal atrophy rate slowed with increasing disease severity in four patient cohorts.”
BackgroundCortical microinfarcts and demyelination affect cognition in cases at high risk for dementia
Kövari, E., Gold, G., Herrmann, F. R., Canuto, A., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2007) · Neurology · doi:10.1212/01.wnl.0000257094.10655.9a · Cited by 128 · cited 1×
“This increases the possibility of misdiagnosis, particularly since microvascular pathology and AD are synergistic in the development of dementia in old age [70,71].”
BackgroundAge and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials
Bernick, C., Cummings, J., Raman, R., Sun, X., & Aisen, P. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3758 · Cited by 85
Diagnosing dementia in the oldest-old
Brumback-Peltz, C., Balasubramanian, A. B., Corrada, M. M., & Kawas, C. H. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.07.008 · Cited by 49 · cited 3×
“Due to the exponential rise in prevalence of AD with age (through approximately 85 years [16]), older individuals will increasingly be more available for clinical trials as compared with younger individuals.”
Background
Cited by
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., & Walhovd, K. B. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.004 · Cited by 799
“…studies, several have found modest acceleration of regional decline with increasing age (Raz et al., 2004a,b, 2005, 2010; Du et al., 2006; Driscoll et al., 2009; Fjell et al., 2009a; Schuff et al., 2010; Thambisetty et al., 2010; Holland et al., 2012a; Taki et al., 2013; Pfefferbaum et al., 2013).”
BackgroundSelf-citationLa Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
“Rates of clinical decline and brain atrophy decreased with age in controls, MCI patients, and AD patients but increased with age in the normal elderly [432].”
BackgroundSelf-citationNewton, J. N., Briggs, A. D. M., Murray, C. J. L., Dicker, D., Foreman, K. J., Wang, H., Naghavi, M., Forouzanfar, M. H., Ohno, S. L., Barber, R. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00195-6 · Cited by 345
Metadata
- Authors
- Holland, D., Desikan, R. S., Dale, A. M., McEvoy, L. K., & Initiative, F. T. A. D. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-02
- Volume
- 7
- Issue
- 8
- Pages
- e42325
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1968895857
- Cited by
- 99
- References
- 25
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.